The expense associated with acquiring and utilizing equipment for self-monitoring of International Normalized Ratio (INR) at one’s residence is a significant consideration for individuals requiring long-term anticoagulation therapy. This expense encompasses the initial purchase of the testing device, as well as the recurring cost of test strips or cartridges necessary for each individual measurement. For example, an individual might incur an upfront charge for the meter itself, followed by regular purchases of consumables required for continued operation.
The significance of understanding the financial aspect resides in its impact on adherence to prescribed anticoagulation regimens. Affordable access to self-testing promotes more frequent monitoring, potentially leading to improved therapeutic control and reduced risk of adverse events such as bleeding or thrombosis. Historically, laboratory-based INR testing was the only option, presenting logistical and financial barriers for many patients. The advent of accessible home testing technology represents a substantial advancement in patient empowerment and proactive healthcare management.
